DK2488513T3 - 2,6-Diaminopyridinforbindelser til behandling af sygdomme forbundet med amyloidproteiner eller til behandling af øjensygdomme - Google Patents

2,6-Diaminopyridinforbindelser til behandling af sygdomme forbundet med amyloidproteiner eller til behandling af øjensygdomme

Info

Publication number
DK2488513T3
DK2488513T3 DK10776598.4T DK10776598T DK2488513T3 DK 2488513 T3 DK2488513 T3 DK 2488513T3 DK 10776598 T DK10776598 T DK 10776598T DK 2488513 T3 DK2488513 T3 DK 2488513T3
Authority
DK
Denmark
Prior art keywords
treatment
diseases
amyloid proteins
compounds
diseases associated
Prior art date
Application number
DK10776598.4T
Other languages
English (en)
Inventor
Heiko Kroth
Wolfgang Froestl
Andrea Pfeifer
Andreas Muhs
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Application granted granted Critical
Publication of DK2488513T3 publication Critical patent/DK2488513T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
DK10776598.4T 2009-10-15 2010-10-14 2,6-Diaminopyridinforbindelser til behandling af sygdomme forbundet med amyloidproteiner eller til behandling af øjensygdomme DK2488513T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09173184A EP2311823A1 (en) 2009-10-15 2009-10-15 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
PCT/EP2010/065439 WO2011045383A2 (en) 2009-10-15 2010-10-14 2, 6 -diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases

Publications (1)

Publication Number Publication Date
DK2488513T3 true DK2488513T3 (da) 2018-01-29

Family

ID=41800516

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10776598.4T DK2488513T3 (da) 2009-10-15 2010-10-14 2,6-Diaminopyridinforbindelser til behandling af sygdomme forbundet med amyloidproteiner eller til behandling af øjensygdomme

Country Status (13)

Country Link
US (2) US8916590B2 (da)
EP (2) EP2311823A1 (da)
JP (1) JP5662460B2 (da)
CN (2) CN104262243B (da)
AU (1) AU2010305770B2 (da)
BR (1) BR112012008843B1 (da)
CA (1) CA2777509C (da)
DK (1) DK2488513T3 (da)
ES (1) ES2657701T3 (da)
MX (1) MX2012004388A (da)
NO (1) NO2488513T3 (da)
RU (1) RU2538208C2 (da)
WO (1) WO2011045383A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
CN104363908B (zh) * 2012-05-30 2017-12-22 霍夫曼-拉罗奇有限公司 吡咯烷基杂环类
EP3423835B1 (en) * 2016-02-29 2023-10-25 Maintect GmbH Predictive markers useful in the treatment of wet age-related macular degeneration
CN106986876B (zh) * 2017-03-20 2019-02-19 北京理工大学 一种靶向标记眼晶体上皮细胞的荧光探针、其制备及应用
US20230087342A1 (en) 2019-09-30 2023-03-23 Nippon Chemiphar Co., Ltd. Azepane derivative

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023A (en) * 1847-03-20 Stocking-loom
BE606550A (da) 1960-07-27
US3651023A (en) 1968-07-02 1972-03-21 Stamicarbon Preparation of polyamides with special properties
SU400583A1 (ru) 1971-07-05 1973-10-01 Донецкое отделение физико органической химии Института физической химии Украинской ССР Способ получения 2, 3-бисметилал\инопиридина
JPS604171A (ja) 1983-06-23 1985-01-10 Showa Denko Kk N−アルキルアミノピラゾ−ル誘導体とその製造法および除草剤
BR9509421A (pt) 1994-10-21 1997-09-30 Innogenetics Nv Novas sequências de genotipos de vírus de hepatite C e uso como agentes profiláticos terapêuticos e diagnósticos
CA2203517A1 (en) 1994-11-10 1996-05-23 Alan M. Laibelman Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
PT992501E (pt) 1995-09-22 2003-01-31 Wakunaga Pharma Co Ltd Derivados de acido piridonacarboxilico como agentes antibacterianos
US6385594B1 (en) 1998-05-08 2002-05-07 Lendingtree, Inc. Method and computer network for co-ordinating a loan over the internet
US6436915B1 (en) 2000-04-07 2002-08-20 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
AU2002303094B2 (en) 2001-03-29 2006-11-23 Eli Lilly And Company N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
WO2003040402A2 (en) 2001-11-09 2003-05-15 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
US7574396B2 (en) 2001-12-04 2009-08-11 Andrew Kalotay Associates, Inc. Method of and apparatus for administering an asset-backed security using coupled lattice efficiency analysis
GB0206723D0 (en) 2002-03-21 2002-05-01 Glaxo Group Ltd Novel compounds
DE10221052A1 (de) 2002-05-10 2003-12-04 Transmit Technologietransfer Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
RU2391341C2 (ru) 2002-09-25 2010-06-10 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение
CA2511599A1 (en) 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20040205019A1 (en) 2003-04-08 2004-10-14 Lendingtree, Inc. Method and system for selecting qualification forms for financial services and financial products
AU2004247013B2 (en) 2003-05-14 2010-07-08 Neurogenetic Pharmaceuticals, Inc. Compounds and uses thereof in modulating amyloid beta
US7732467B2 (en) * 2003-05-15 2010-06-08 Alzheimer's Institute Of America, Inc. Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
CA2526487A1 (en) 2003-06-30 2005-01-06 Daiichi Pharmaceutical Co., Ltd. Heterocyclic methyl sulfone derivative
TWI301760B (en) * 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
JP5156378B2 (ja) 2004-09-22 2013-03-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ MDM2とp53の間の相互作用の阻害剤
WO2006039327A2 (en) 2004-10-01 2006-04-13 Merck & Co., Inc. Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve
WO2006065204A1 (en) 2004-12-14 2006-06-22 Astrazeneca Ab Substituted aminopyridines and uses thereof
US20070073504A1 (en) 2005-09-26 2007-03-29 Bristol-Myers Squibb Company Configurable component handling device
US7882025B1 (en) 2005-11-18 2011-02-01 Federal Home Loan Mortgage Corporation (Freddie Mac) Systems and methods of a mortgage pricing service
CN101330923B (zh) 2005-12-12 2015-01-07 Ac免疫有限公司 治疗性疫苗
RU2015111675A (ru) 2005-12-12 2015-08-10 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
EP1829867A1 (en) 2006-03-03 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Imidazole compounds having pharmaceutical activity towards the sigma receptor
PT3279663T (pt) * 2006-03-15 2021-09-24 Brigham & Womens Hospital Inc Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
US20080109347A1 (en) 2006-08-22 2008-05-08 Pilcher John W System and methods for constructing loans
JP5292300B2 (ja) * 2006-11-24 2013-09-18 エーシー イミューン ソシエテ アノニム 例えばアルツハイマー病のようなアミロイドまたはアミロイド様タンパク質に関連する疾患の治療のためのn−(メチル)−1h−ピラゾール−3−アミン誘導体、n−(メチル)−ピリジン−2−アミン誘導体、およびn−(メチル)−トリゾール−2−アミン誘導体
US8084613B2 (en) * 2007-05-14 2011-12-27 Nippon Soda Co., Ltd. Tetrazoyloxime derivative and plant disease control agent
US8244618B1 (en) 2009-01-08 2012-08-14 Amherst Holdings, LLC Loan information analysis system and method
EP2311823A1 (en) * 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases

Also Published As

Publication number Publication date
NO2488513T3 (da) 2018-05-26
EP2311823A1 (en) 2011-04-20
CN104262243A (zh) 2015-01-07
WO2011045383A3 (en) 2011-06-30
CN102656161B (zh) 2015-02-18
RU2538208C2 (ru) 2015-01-10
US20110092537A1 (en) 2011-04-21
BR112012008843A2 (pt) 2022-02-08
WO2011045383A2 (en) 2011-04-21
US9701660B2 (en) 2017-07-11
US20150023950A1 (en) 2015-01-22
BR112012008843B1 (pt) 2022-08-30
MX2012004388A (es) 2012-06-08
EP2488513B1 (en) 2017-12-27
AU2010305770A1 (en) 2012-05-03
JP2013507428A (ja) 2013-03-04
CN102656161A (zh) 2012-09-05
CN104262243B (zh) 2017-04-12
CA2777509A1 (en) 2011-04-21
JP5662460B2 (ja) 2015-01-28
ES2657701T3 (es) 2018-03-06
EP2488513A2 (en) 2012-08-22
RU2012119757A (ru) 2013-11-20
CA2777509C (en) 2015-06-02
US8916590B2 (en) 2014-12-23
AU2010305770B2 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
MY173699A (en) Novel compounds for the treatment of diseases associated with amyloid of amyloid-like proteins
CA2883095C (en) Antibody and protein formulations
WO2008061795A3 (en) N- (methyl) -1h- pyrazol- 3 -amine, n- (methyl) -pyridin-2-amine and n- (methyl) -thiaz0l-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
UA101167C2 (ru) Фармацевтическая композиция, предназначенная для лечения глазной болезни
WO2013049234A3 (en) Dual function proteins for treating metabolic disorders
WO2008101985A3 (en) Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
WO2012097213A3 (en) Methods for diagnosing and treating eye-length related disorders
EP2566380A4 (en) METHOD AND SYSTEM FOR THE IMAGING OF AMYLOID BETA IN THE NETWORK OF THE EYE FOR THE TREATMENT OF MORBUS ALZHEIMER
WO2010115843A3 (en) Pharmaceutical composition
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2014204816A3 (en) Method for assessing protein identity and stability
DK2470191T3 (da) Fremgangsmåder og præparater til forebyggelse eller behandling af oftalmiske tilstande
WO2012045882A3 (en) Phosphospecific antibodies recognising tau
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
EP1940373A4 (en) INOSITOL DERIVATIVES AND THEIR USES IN THE TREATMENT OF ILLNESSES CHARACTERIZED BY ABNORMAL PROTEIN FOLLOWING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE
NO20092633L (no) Ernaeringstilskuddsammensetning for behandling av okulare sykdommer
AU2016255474B2 (en) Application of PI4KIIIα protein and related membrane protein complex in treating Alzheimer's disease
DK2488513T3 (da) 2,6-Diaminopyridinforbindelser til behandling af sygdomme forbundet med amyloidproteiner eller til behandling af øjensygdomme
BR112013029713A2 (pt) método de tratamento de distúrbios da visão
WO2016005466A3 (en) IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
WO2012149145A3 (en) Ocular detection of amyloid proteins
WO2008127654A3 (en) Methods and compositions for intra-articular coagulation proteins
WO2011022357A3 (en) Fast acting snare-cleaving enzymes
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
WO2016040891A3 (en) In vitro compositions comprising human sample and amyloid targeting agent